Table III.

Recognition of modified Melan-A derived peptides by Ag-specific TILN from HLA-A2+ melanoma patients.

Peptide SequenceTIL LAU 132TIL LAU 203
Peptide [nM] 50%aRelative ActivitybPeptide [nM] 50%Relative Activity
AAGIGILTV301601
ALGIGILTV6000.05>1000<0.06
AMGIGILTV>1000<0.03>1000<0.06
LAGIGILTV1.520610
MAGIGILTV2.51287.5
EAAGIGILTV310125
ELAGIGILTV0.05600230
EMAGIGILTV0.05600230
EALGIGILTV4000.0710000.06
EAMGIGILTV>1000<0.03>1000<0.06
YAAGIGILTV130520
FAAGIGILTV0.05600160
  • a Relative antigenic activity of Melan-A peptides was measured as described in the legend to Figure 4. The peptide concentration required to obtain 50% of maximal activity ([nM] 50%) was then determined for each peptide.

  • b The relative antigenic activity was calculated as the [nM] 50% for the reference peptide Melan-A27–35 divided by that of the corresponding analog peptide.